Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial

P. Cannon, Christopher; H. McCabe, Carolyn; G. Wilcox, Robert; Langer, Anatoly; Caspi, Abraham; Berink, Peter; López-Sendón, José; Toman, Jiřı́; Charlesworth, Andrew; J. Anders, Robert; C. Alexander, John; M. Skene, Allan; Braunwald, Eugene

doi:10.1161/01.cir.102.2.149

Public

Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial

Published in Circulation • Jul 11, 2000

Authors:

Christopher P. Cannon

Carolyn H. McCabe

Robert G. Wilcox

Abstract

BACKGROUND: Although intravenous glycoprotein IIb/IIIa inhibitors are beneficial in patients with acute coronary syndromes, prolonged oral IIb/IIIa inhibition might provide an additional reduction in recurrent events. METHODS AND RESULTS: Investigators at 888 hospitals in 29 countries enrolled 10 28...

Subject

Medicine

Myocardial infarction

TIMI

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!